Durata Therapeutics to Present at Credit Suisse 2012 Healthcare Conference

Durata Therapeutics to Present at Credit Suisse 2012 Healthcare Conference

Durata TherapeuticsAllison WeyVice President, Investor Relations and Public Affairs(312) 612-5462orWhite Oak Communications, Inc.Jed Weiner(847) 392-4186

Durata Therapeutics (NASDAQ: DRTX) today announced that Durata Chief Executive Officer Paul R. Edick will present an overview of the company at the Credit Suisse Healthcare Conference. The Durata presentation will take place at The Arizona Biltmore, Phoenix, Arizona on Thursday, November 15, 2012 at 3:00 p.m. MST.

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed enrollment in two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with ABSSSI.

Any statements in this press release about Durata’s future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.